Prevalence of Wildtype Amyloid After TAVR

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-20

Study Completion Date

2019-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Those with abnormal vital signs after TAVR need to be willing to obtain a bone scan to evaluate for wildtype amyloidosis. Positive bone scan findings will require evaluation for primary amyloidosis with blood and urine monoclonal immunoglobulin testing. Primary amyloidosis is a different type of disease which requires different treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR

NCT06015997

ATTR Amyloidosis Wild Type Severe Aortic Stenosis Aortic Valve Stenosis +1 more

NOT_YET_RECRUITING

Cardiac Amyloidosis in Patients With Aortic Stenosis

NCT07170306

Aortic Stenosis Transthyretin Amyloid Cardiomyopathy

NOT_YET_RECRUITING

Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.

NCT02260466

Heart Disease Aging Amyloidosis +1 more

ACTIVE_NOT_RECRUITING NA

Screening for Amyloidosis Before Aortic Valve Elective Replacement

NCT04869631

Amyloidosis Aortic Valve Stenosis

ACTIVE_NOT_RECRUITING

Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot

NCT04363294

Aortic Valve Stenosis Cardiac Amyloidosis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research is interested in determining how common wildtype amyloidosis is after transcatheter aortic valve replacement (TAVR). Amyloidosis is a condition characterized by abnormal protein which can accumulate and impair various organs, including the heart. Research suggests that amyloidosis might be common among TAVR patients, but it is a condition that is not routinely evaluated for. We suspect that wildtype amyloidosis may be especially common among patients with abnormal vital signs after their TAVR procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients that underwent a TAVR procedure at the Malcolm Randall VA Medical Center.
* Implant of current generation TAVR (i.e. Sapien S3, Evolut R, or Evolut Pro).
* Willingness to obtain bone scintigraphy if evidence of impaired hemodynamics after valve deployment.
* Willingness to have blood drawn
* Willingness to complete SF12 quality of life KCCQ